EHA 2019 | Implications of apoptotic MSCs inducing PG-E2

Name: Implications of apoptotic MSCs inducing PG-E2
Uploaded: 2019-06-14T00:00:00.000Z
Duration: 1 min 2 s
Description: Francesco Dazzi, MD, PhD, King’s College London, London, UK, explains that the therapeutic effect of the mesenchymal stromal cells (MSCs) includes reprogramming monocytes to release the prostaglandin PG-E2. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Francesco Dazzi • 14 Jun 2019

EHA 2019

General

Francesco Dazzi, MD, PhD, King’s College London, London, UK, explains that the therapeutic effect of the mesenchymal stromal cells (MSCs) includes reprogramming monocytes to release the prostaglandin PG-E2. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.